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Abstract
Background: Wilson disease (WD) is an autosomal recessive disorder of human copper metabolism characterized by
copper accumulation in the liver due to impaired excretion of copper into the bile. Brain accumulation of copper may
cause neuropsychiatric symptoms. Trientine (triethylenetetramine dihydrochloride) is a copper-chelating agent used to
treat patients with WD. Trientine has been considered an option for initial treatment and maintentance therapy of WD
due to its safety profile.
Case presentation: A 40 year old female with a recent diagnosis of WD was started on treatment with trientine for
her WD. Within one month she developed profound bloody diarrhea unresponsive to medical treatment. Trientine was
discontinued and a colonoscopy with biopsy showed moderately active ileitis and moderate to severe pancolitis,
consistent with a drug induced mucosal injury. The colitis improved immediately upon withdrawal of trientine, and
recurred when medication was rechallenged because of worsened WD symptoms. After second compulsory
discontinuation of trientine, she remained on zinc therapy for her WD and her colitis resolved by time.
Conclusion: Drug induced colitis is a very rare side effect of trientine. Although trientine therapy is well tolerated and
less side effects are reported with this medication than penicillamine, colitis can occur during trientine treatment. Zinc
therapy may be an effective alternative for treatment of WD in patients experiencing side effects from chelation
therapy.
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Background
Wilson disease (WD) is an autosomal recessive disorder
of copper metabolism with prevalence of ~1:30,000. Un-
treated, the disease leads to progressive hepatic failure
or debilitating neuropsychiatric symptoms [1]. Drug re-
actions due to d- Penicillamine, the first oral copper
chelating agent, led to the development of triethylenete-
tramine dihydrochloride (trientine). The first reported
use of trientine was by Walshe in 1969 to treat a child
who developed penicillamine-induced nephrotoxicity [2].
Since, trientine has been used to treat WD with rare re-
ported side effects described in case reports or small
case series. Here we report on a WD patient on trientine
therapy who experienced colitis and discuss her manage-
ment and treatment.
Case presentation
A 40 year old female with a recent diagnosis of WD
with predominant neuropsychiatric symptoms was re-
ferred. She was initially treated by her primary care
physician for a month with escitalopram, 5 mg daily. She
noted increased agitation, so escitalopram was discontin-
ued. Over the next 8 months, she did not complain of
depression, however developed perioral and fingertip
paresthesias, gait unsteadiness and slowed speech. Fur-
ther testing included electromyography, and spinal and
cranial magnetic resonance imaging, all reported as nor-
mal. Additional testing leading to the diagnosis of WD
included a ceruloplasmin of 3 mg/dl (14–47.8), serum
copper of 0.35 μg/dl (0.75–1.45) and a 24 h urıne copper
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excretion of 149 μg (15–60). Kayser-Fleisher rings were
seen on ophthalmological evaluation. She was started on
treatment for WD with trientine 250 mg three times
daily. Within one month she developed profound bloody
diarrhea with negative cultures for enteric pathogens, in-
cluding clostridium difficile, and was unresponsive to
immodium, ciprofloxacin, and lomotil. Trientine was
discontinued and a colonoscopy with biopsy was per-
formed. Biopsies showed moderately active ileitis and
moderate to severe pancolitis. The changes were diffuse
with an increase in lamina propria lymphoplasmacytic
infiltration, diffuse injury to crypts with marked mucin
depletion and extensive cryptitis. The crypt distortion
was mild and there was no granulomatous inflammation
or paneth cell metaplasia. The histologic changes were
suggestive of active colitis, but were etiologically non-
specific. Given her history, the colonic changes were
consistent with a drug induced mucosal injury.
She was started on prednisone for the colitis. Three
days later she became severely manic with psychotic fea-
tures, prompting psychiatry consultation. She was
treated symptomatically with atypical antipsychotics to
which she experienced side effects at very low doses
(Olanzapine 2.5 mg, Quetiapine 50 mg). She was main-
tained on zinc, 50 mg, three times daily for her WD
while the prednisone was tapered off. Her colitis symp-
toms resolved. On follow-up sigmoidoscopy, colitis was
resolved.
After an initial improvement, her psychosis worsened
and she required hospitalization. Due to neuropsychi-
atric symptoms, trientine was restarted in addition to
the zinc for her WD. She was transferred to the medical
floor after several days due to recurrent colitis with mul-
tiple grossly bloody bowel movements. Trientine was
discontinued and she was maintained on zinc therapy
for her WD. Evaluation for other causes of colitis in-
cluded negative blood and stool cultures, including C.
Difficile, campylobacter, salmonella and norovirus. She
also had no antibodies to Saccharomyces cerevisiae, nor-
mal Ig A and Ig G levels, and ANCA and p-ANCA were
negative. Repeat colonoscopy showed moderate to severe
active colitis and proctitis, and the degree of colitis was
significantly more severe than on prior biopsies. There
was extensive acute inflammation with cryptitis and
crypt abscess formation and multiple foci of fresh and
healing ulceration. Occasional branching crypts and
focal crypt shortening was noted. Similar to the prior bi-
opsies, granulomas, pseudopyloric metaplasia or paneth
cell metaplasia were not seen (Fig. 1a&1b). While the
histologic differential diagnosis included prolonged in-
fectious, self-limited type colitis and inflammatory bowel
disease. Given the clinical features, drug induced colitis
was favored. With time and continuation of her zinc
therapy for her WD, her colitis resolved.
Her psychiatric symptoms also improved, and nine
months after the onset of psychiatric symptoms she was
symptoms-free, having returned to work and baseline
social activities. Four years later she continues in remis-
sion psychiatrically with stable liver function. She re-
mains on zinc maintenance therapy for her WD.
Discussion
Medical treatment regimens for WD include copper
chelators and zinc salts. Chelating agents are generally
first line therapy for symptomatic patients because of
their higher decoppering potential compared to zinc
salts that indirectly reduce copper by blocking intestinal
absorption. D-penicillamine, the first oral copper chelat-
ing agent [3], is commonly used worldwide. However in-
tolerance and serious side effects such as immune
complex nephritis, nephrotic syndrome, systemic lupus
erythematosus and bone marrow suppression led to the
use of trientine. [2]. Trientine is an effective initial treat-
ment and maintentance therapy for WD [4]. Due to its
better safety profile, trientine was included as an option
for first line and maintenance therapy for WD in Ameri-
can Association for the Study of Liver Diseases (AASLD)
and European Association for the Study of Liver Dis-
eases (EASL) guidelines [5, 6]. Rare side effects reported
for trientine include iron deficiency, systemic lupus
Fig. 1 a. Low magnification of the biopsy showing diffuse infiltration of the colonic lamina propria by lymphoplasmacytic inflammatory infiltrate,
slight crypt distortion, focal crypt shortening, and crypt abscess. b. Higher magnification showing mucin depletion of the crypt epithelium and
reactive changes. Cryptitis can also be easily seen at this magnification
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erythematosus, dystonia, muscular spasm and myasthe-
nia gravis [7]. Only 6–18 % of orally administered trien-
tine is systemically absorbed [8].
Effects of trientine on the colon were first noted by
Dahlman et al. in 1995, profiling two WD patients that
experienced colitis while on trientine [9]. Their first pa-
tient had experienced side effects with penicillamine, de-
veloping uveitis, proteinuria and ANA positivity, and
was changed to trientine. Endoscopic evidence of duo-
denitis and colitis was seen four months after exposure
to trientine. Although trientine was initially withdrawn it
was later restarted along with steroid. The steroid was
eventually withdrawn, and the patient remained on tri-
entine without diarrhea or recurrence of colitis.
The second WD patient was cirrhotic and was initially
started on trientine. Diarrhea developed that ceased with
the withdrawal of a neuroleptic drug, and trientine was
continued. Months later, when symptoms started with a
gastroenteritis seen in the whole family, the patient de-
veloped bloody diarrhea and had colonoscopic evidence
of colitis. After withdrawal of trientine, colitis recurred
when penicillamine was administered, suggesting an
underlying inflammatory bowel disease.
In our WD patient, trientine was chosen as initial
treatment. Colitis developed within a month of exposure
to the drug, earlier than in the cases reported above. Her
symptoms improved immediately upon withdrawal of
trientine, and colitis recurred with rechallenge to this
medication. The colitis was visible on colonoscopy from
the rectum to the transverse colon. Histologic features
included cryptitis, crypt abscesses and multiple foci of
fresh and healing ulcerations. The histologic changes are
not specific, and could be seen in infectious colitis and
evolving inflammatory bowel disease. The lack of well-
developed features of chronicity like established crypt
architectural distortion and paneth and the timing of the
colitis were most helpful in making a diagnosis of trien-
tine colitis, with features similar to those reported in
previous cases [9]. The pathophysiological mechanism
for the development of colitis is unknown. As noted,
there is poor intestinal absorption of trientine from the
gut, and the trigger for developing colitis may be a local
reaction with the colonic epithelium rather than of auto-
immune origin, especially since the reaction was limited
to the time of medication exposure.
Treatment with a chelating agent was warranted in
our patient with symptomatic disease with neuropsychi-
atric features dominating the clinical presentation. Due
to the continued severe neuropsychiatric symptoms, the
re-challenge with trientine was justified. It is worth no-
tion that the steroids required for treatment of trientine
induced colitis complicated the differential diagnosis of
her psychosis. However, the duration of psychosis
(months after steroids were discontinued) and the lack
of exacerbation with another challenge of prednisone led
to the working diagnosis of psychosis secondary to WD
rather than steroid induced psychosis. After the with-
drawal of trientine, the patient was effectively treated
with zinc therapy. Zinc salts induce intestinal epithelium
to produce cytosolic metallothioneins that effectively se-
quester copper and block new copper absorption. While
zinc is indicated for maintenance therapy for WD or ini-
tial treatment of asymptomatic WD patients, zinc was
used for first line treatment of some patients with
neurological WD [10]. Though treatment with zinc can
sometimes cause gastric side effects [11] and the
achievement of a negative copper balance is slower
with zinc, in patients such as ours, zinc therapy was
effective over time. Since our patient had psychiatric
symptoms, she was treated for these independent of
the WD, and was able to withdraw psychiatric therapy
over 1–2 years time.
At the time of the reporting of the prior cases of trien-
tine colitis, zinc therapy was a less well accepted alterna-
tive treatment of WD. Therefore the re-trial of the drug
and attempts at steroid desensitization were warranted.
Given the numerous reports demonstrating the efficacy
of zinc therapy for WD, there would no longer be justifi-
cation for desensitization to trientine or d-penicillamine
in intolerant patients.
Conclusion
Because WD is a rare disease and trientine is an orphan
drug, controlled trials that demonstrate the true inci-
dence of medication side effects with adequate sample
size sufficient to be graded as high-quality studies are
not available. It is our experience that trientine therapy
is well tolerated, and less side effects are reported with
this medication than penicillamine. However drug in-
duced colitis can occur during trientine treatment, and
clinicians need to be aware of this entity if their patient
develops a diarrheal illness while on this therapy. Re-
challenge with trientine is not warranted unless there is
a known intolerance to zinc therapy. Zinc therapy may
be an effective alternative for treatment of WD in pa-
tients experiencing side effects from chelation therapy.
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